The global genomic urine testing market is on a fast growth trajectory. Valued at USD 148.23 million in 2024, the market is expected to reach USD 319.14 million by 2034, expanding at a CAGR of 7.94% over the forecast period. This growth is driven by its increasing application in early disease detection, particularly in conditions such as bladder cancer.
Genomic urine testing is transforming diagnostic capabilities. It enables the early detection of serious diseases such as kidney disorders, diabetes, urinary tract infections, liver conditions, and especially bladder cancer. These tests analyze urine samples for genetic mutations that can indicate disease well before physical symptoms emerge, offering an edge in preventive and personalized healthcare.
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/download-databook/5779
Unlike conventional urine tests, genomic versions offer insights into tumor biology, recurrence risks, and treatment responses. This makes them essential for early diagnosis and patient-specific therapeutic planning, helping to improve survival outcomes and reduce healthcare costs.
The market was valued at USD 148.23 million in 2024.
It is projected to grow at a CAGR of 7.94% from 2025 to 2034.
By 2034, the market is expected to surpass USD 319.14 million.
North America currently holds the largest market share.
The Asia Pacific region is forecasted to grow at the fastest pace over the next decade.
In January 2025, the Indian Biological Data Centre (IBDC) initiated efforts to make genetic data more accessible. By supporting tailored genomic tools for the Indian population, this initiative enhances precision medicine research and bolsters India’s standing in the global genomics industry.
Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5779
In April 2025, Fujirebio Holdings and its subsidiary Fluxus, Inc., received a $4.5 million grant from the GHIT Fund to develop an ultra-sensitive POC urine test for tuberculosis. This innovative project will increase access to accurate TB diagnostics in low-resource settings.
Artificial intelligence is reshaping genomic urine testing. It helps process massive genomic datasets with greater accuracy, speed, and efficiency. AI algorithms assist in identifying mutations and sequencing errors, making diagnostic results more precise.
For example, in April 2025, GeneDx announced the acquisition of Fabric Genomics, a pioneer in AI-powered genomic interpretation. This move will combine decentralized testing models with centralized AI insights, advancing the field of personalized medicine.
The growing elderly population, combined with smoking and occupational exposure to carcinogens, has led to a rise in bladder cancer cases. These trends significantly increase the demand for early, non-invasive diagnostic tools like genomic urine tests.
Hospital pharmacies lead the market in 2024 due to their integral role in managing patient medications, ensuring proper drug compounding, and optimizing treatment plans. Their close coordination with prescribers enhances the efficacy of test-based medication management.
Meanwhile, specialty pharmacies are expected to experience the fastest growth due to their role in managing complex or chronic conditions that require tailored treatment and frequent monitoring.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
Despite their potential, genomic urine tests are expensive—often 2 to 3 times the cost of conventional tests. The large volumes of data they generate also require advanced storage and analytical systems. These cost-related barriers can limit widespread adoption, especially in developing regions.
Recent innovations in Next-Generation Sequencing (NGS) have greatly improved the ability to analyze the urinary microbiome and detect pathogens that traditional urine cultures may miss. Though current standard tests like Ctx still dominate, NGS is positioning itself as a reliable and future-ready solution, offering new opportunities for diagnostic companies.
North America dominates the genomic urine testing landscape, thanks to its advanced healthcare infrastructure, robust electronic health record (EHR) systems, and major investments in genomics and AI. The presence of leading research institutions and biotech firms further drives innovation and adoption.
In January 2025, Tempus, a major U.S.-based genomics company, launched its xH whole-genome sequencing assay, marking a key milestone in whole-genome clinical diagnostics.
Asia Pacific is poised for the fastest CAGR between 2025 and 2035. With rising healthcare expenditure, improved access to genomic services, and growing interest in AI-based diagnostics, countries in this region are catching up quickly.
May 2025: NeoGenomics, Inc. launched the PanTracer Family, a suite of genomic profiling tests for solid tumors.
June 2025: BioAro unveiled PanOmiQ Research, combining AI and multi-omics for faster drug discovery.
March 2025: Illumina Inc. and Nashville Biosciences completed the sequencing of 250,000 genomes for the Alliance for Genomic Discovery (AGD) initiative.
The genomic urine testing market is undergoing rapid transformation, supported by innovation in sequencing, AI integration, and increased awareness of early detection in cancer care. While high costs remain a hurdle, the rise in chronic diseases, government-backed initiatives, and technological advancements provide a strong foundation for continued growth. With North America leading the charge and Asia Pacific not far behind, the market is well-positioned for sustained expansion through 2034.
To access the full Market Report : https://www.towardshealthcare.com/price/5779
The global metagenomics market is poised for robust growth over the next decade, projected to surge from USD 2.36 billion… Read More
The global automated blood processing equipment market is witnessing remarkable momentum, projected to grow from USD 2.12 billion in 2024… Read More
The global bacteriophage market is experiencing a significant surge as the world grapples with the growing challenge of antimicrobial resistance… Read More
The laboratory balances and scales market is on a steady growth trajectory, driven by expanding research activities and a surge… Read More
The global gastrointestinal drugs market is experiencing steady growth, expected to rise from USD 40.21 billion in 2024 to USD… Read More
The global low-input sequencing technologies market is experiencing significant momentum and is set for notable growth from 2025 to 2034.… Read More